Skip to main content

Advertisement

SpringerLink
Log in

Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia

  • Original article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the impact of Ga-68 DOTATOC PET/CT on diagnosis and therapeutic management of patients with multiple endocrine neoplasia (MEN).

Materials and methods

We did 28 Ga-68 DOTATOC PET/CT in 21 MEN patients (10 female, 11 men; mean age 41.3 years). 109 lesions detected were classified into MEN-associated lesions [i.e., neuroendocrine tumors (NET)] and non-MEN-associated lesions for PET, CT, and PET/CT. The impact of Ga-68 DOTATOC PET/CT on diagnosis and therapeutic management of patients with MEN were assessed by the records of the interdisciplinary NET tumor board including histopathological findings, clinical and radiological follow-up.

Results

Ga-68 DOTATOC PET/CT had an impact on diagnosis and therapeutic management in 10/21 (47.6 %) MEN patients. For detecting NET lesions in MEN patients Ga-68 DOTATOC PET/CT reached a sensitivity/specificity of 91.7 %/93.5 %. There was a significant difference for the detection rate between Ga-68 DOTATOC PET/CT and CT alone (p < 0.001) both using contrast-agent (p = 0.002) or not (p < 0.001) and also a significant difference between contrast-enhanced (CE-) CT and non-CE-CT alone (p = 0.006).

Conclusions

GA-68 DOTATOC PET/CT allows a high detection rate of NET lesions in the context of MEN-1 syndrome as well as influence therapeutic management in nearly up to half of the patients. GA-68 DOTATOC PET/CT should include a CE-CT to improve MEN-associated NET lesion detection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. 2006;2:1–38.

    Google Scholar 

  2. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab. 2001;12:173–8.

    Article  PubMed  CAS  Google Scholar 

  3. Iler MA, King DR, Ginn-Pease ME, O’Dorisio TM, Sotos JF. Multiple endocrine neoplasia type 2A: a 25-year review. J Pediatr Surg. 1999;34:92–6.

    Article  PubMed  CAS  Google Scholar 

  4. Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer. 2010;9:449–57.

    Article  PubMed  CAS  Google Scholar 

  5. Georgitsi M. MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. Best Pract Res Clin Endocrinol Metab. 2010;24:425–37.

    Article  PubMed  CAS  Google Scholar 

  6. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev. 2004;25:568–80.

    Article  PubMed  Google Scholar 

  7. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of Multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91:101–9.

    Article  PubMed  CAS  Google Scholar 

  8. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.

    Article  PubMed  CAS  Google Scholar 

  9. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68 Ga for medical application. J Nucl Med. 2007;48:1741–8.

    Article  PubMed  CAS  Google Scholar 

  10. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68 Ga. Eur J Nucl Med Mol Imaging. 2005;32:478–85.

    Article  PubMed  CAS  Google Scholar 

  11. Pfannenberg C, Schraml C, Schwenzer N, Werner M, Muller M, Bares R, et al. Comparison of [68 Ga]DOTATOC-PET/CT and whole-body MRI in staging of neuroendocrine tumors. Cancer Imaging. 2011;11:38–9.

    Article  Google Scholar 

  12. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology. 1998;206:143–50.

    PubMed  CAS  Google Scholar 

  13. Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95:88–97.

    Article  PubMed  CAS  Google Scholar 

  14. Pelage JP, Soyer P, Boudiaf M, Brocheriou-Spelle I, Dufresne AC, Coumbaras J, et al. Carcinoid tumors of the abdomen: CT features. Abdom Imaging. 1999;24:240–5.

    Article  PubMed  CAS  Google Scholar 

  15. Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, et al. 68 Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med. 2011;52:697–704.

    Article  PubMed  Google Scholar 

  16. Mayerhoefer ME, Schuetz M, Magnaldi S, Weber M, Trattnig S, Karanikas G. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Eur Radiol. 2012;22:938–46.

    Article  PubMed  Google Scholar 

  17. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 1998;22:588–92.

    Article  PubMed  CAS  Google Scholar 

  18. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414–21.

    Article  PubMed  CAS  Google Scholar 

  19. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. E Eur J Nucl Med. 2001;28:1671–6.

    Article  CAS  Google Scholar 

  20. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43:66–71.

    PubMed  Google Scholar 

  21. Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF, et al. C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res. 2010;42:209–14.

    Article  PubMed  CAS  Google Scholar 

  22. Li S, Beheshti M. The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets. 2005;5:139–48.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Charité, Universitätsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany

    Vera Froeling, Martin H. Maurer, Christian Scheurig-Muenkler, Alexander Beck & Bernd Hamm

  2. Department of Nuclear Medicine, Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13553, Berlin, Germany

    Florian Elgeti, Winfried Brenner & Nils F. Schreiter

  3. Department of Radiology, Charité, Universtitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany

    Thomas J. Kroencke

  4. Department of Gastroenterology, Charité, Universitätsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany

    Ulrich-Frank Pape

Authors
  1. Vera Froeling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florian Elgeti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin H. Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Scheurig-Muenkler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas J. Kroencke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulrich-Frank Pape
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bernd Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Winfried Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nils F. Schreiter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nils F. Schreiter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Froeling, V., Elgeti, F., Maurer, M.H. et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med 26, 738–743 (2012). https://doi.org/10.1007/s12149-012-0634-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-012-0634-z

Keywords

Search

Navigation